Abstract:Objectives: Approximately 40% of patients with colorectal cancer will develop liver metastases. Hepatic arterial infusion chemotherapy (HAIC) represents a valuable treatment option, with curative, palliative, or adjuvant intent. The aim of our study was to describe technical considerations, safety, and oncological outcomes of patients receiving HAIC. Materials and methods: All patients who underwent percutaneous hepatic arterial port placement in our institution between 2004 and 2021 were included in this retrospective analysis. Demographic, anatomical and technical data were collected. Tumor response was assessed using RECIST 1.1. Kaplan-Meier estimates were used for overall survival (OS) and hepatic progression-free survival (PFS). Adverse events (AEs) were graded using the Clavien-Dindo classification. Results: A total of 360 patients (median age, 58.6 years [interquartile range (IQR): 49.5-65.4]; 208 men [57.8%]) were included. Percutaneous hepatic arterial port placement was successful in 87.9% of cases, resulting in 379 port placements (431 attempts). Overall, 394 HAIC courses were delivered, mostly oxaliplatin-based (94.7%), with a median of 6 cycles per course (IQR: 3-8). AEs (all grades) were observed in 42.0% of ports (grade IIIb-V: 1.1%). Most port dysfunctions could be resolved, resulting in a 73.1% rate of HAIC resumption, without impact on OS. Median OS was 22 months (IQR: 18-24), and median hepatic PFS was 11 months (IQR: 9.5-13). Tumor downstaging allowed surgery in 35.6% of patients, with significantly longer median OS than non-operated patients (39 months [IQR: 33-79] versus 14 months [IQR: 12-16], p < 0.001). Conclusion: This retrospective cohort study demonstrates the feasibility, safety, and efficacy of percutaneous hepatic arterial port placement with an impact on survival for selected patients. Clinical relevance statement: Percutaneous hepatic arterial port placement is feasible, safe and effective with an impact on the survival of selected patients. Key points: Hepatic arterial infusion chemotherapy provides promising tumor response and overall survival, especially in cases of resection/ablation. Total complication rate of hepatic arterial infusion chemotherapy port use is high, but serious complications are rare. Port revision is often necessary but allows the resumption of hepatic arterial infusion chemotherapy without affecting overall survival.

Percutaneous Laser Ablation of Hepatic Tumors Located in the Portacaval Space: Preliminary Results

Percutaneous microwave ablation liver partition and portal vein embolization for planned hepatectomy due to large gastrointestinal stromal tumor metastases: A case report.

Percutaneous Radiofrequency Ablation of Hepatic Tumors During Temporary Venous Occlusion

Percutaneous Ablation of Hepatic Tumors at the Hepatocaval Confluence Using Irreversible Electroporation: A Preliminary Study

Radiofrequency Ablation Combined with Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma.

Preliminary Results of Ultrasound-Guided Laser Ablation for Unresectable Metastases to Retroperitoneal and Hepatic Portal Lymph Nodes.

Clinical Assessment of Percutaneous Microwave Ablation for Liver Tumors Abutting Special Locations under B Ultrasound Guidance

Imaging characteristics and intervention therapy for hepatic artery-portal vein shunts in patients with primary liver carcinoma

Safety and effectiveness of balloon catheter-assisted ultrasound-guided percutaneous microwave ablation in difficult-site liver cancer

Percutaneous Radiofrequency Ablation for Liver Tumors: is It Safer and More Effective in Low-Risk Areas Than in High-Risk Areas?

Treatment Response and Preliminary Efficacy of Hepatic Tumour Laser Ablation under the Guidance of Percutaneous and Endoscopic Ultrasonography.

Precise Microwave Ablation in Hepatic Neoplasms Adjacent to High-Risk Structures: a Prospective Pilot Study

[The Combination of Percutaneous Iohexol-Ethanol Injection with Radiofrequency Ablation for the Treatment of Primary Liver Cancer in High-Risk Locations].

Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation

Microwave ablation in combination with TACE for the treatment of primary hepatic carcinoma

Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study

Safety and efficacy of percutaneous arterial port Implantation for Hepatic Arterial Infusion Chemotherapy

Stereotactic Image-Guided Microwave Ablation for Malignant Liver Tumors—A Multivariable Accuracy and Efficacy Analysis

Determinants of Survival of Ablation Treatment for Portal Vein Tumor Thrombus in Patients With Hepatocellular Carcinoma

A Study on Feasibility and Safety

Long-term Outcomes of Endoscopic Ultrasound-Guided Laser Ablation for Liver Tumors in the Caudate Lobe: 5 Years of Experience